Current Atherosclerosis Reports

, Volume 9, Issue 5, pp 359–366

Rimonabant: The role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients

  • Christopher T. Dibble
  • Eli V. Gelfand
  • Christopher P. Cannon
Article

Abstract

Rimonabant is a selective blocker of the CB1 cannabinoid receptor that has been developed for treatment of abdominal obesity, dyslipidemia, and control of diabetes. Four randomized clinical trials have demonstrated that following 1 year of treatment, 20 mg/d of rimonabant is associated with greater weight loss and reduction in waist circumference compared with placebo. Therapy with rimonabant is associated with favorable changes in serum high-density lipoprotein and triglycerides, as well as with an improvement in glycemic control among obese type 2 diabetic patients. Rimonabant appears to be well tolerated, with the most common side effects being nausea, anxiety, and depressive symptoms. Rimonabant is a novel agent that has the potential to be a useful adjunct to lifestyle and behavior modification in treatment of abdominal obesity, dyslipidemia, and dysglycemia.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Christopher T. Dibble
  • Eli V. Gelfand
  • Christopher P. Cannon
    • 1
  1. 1.Cardiovascular Division, Department of MedicineBrigham and Women’s Hospital, TIMI Study GroupBostonUSA

Personalised recommendations